Zydus Wellness

Why is Zydus Wellness Ltd falling/rising?

As of 01-Sep, Zydus Wellness Ltd's stock price is at 528.00, down 0.46%, and has underperformed its sector. Despite strong financial metrics, the stock's decline is attributed to a year-over-year profit drop and recent underperformance relative to the sector.

As of 01-Sep, Zydus Wellness Ltd's stock price is currently at 528.00, reflecting a decrease of 2.45 (-0.46%). The stock has underperformed its sector today by 1.17%. Despite a recent rise in investor participation, indicated by a 54.93% increase in delivery volume on August 31, the stock's performance over the past month shows a decline of 8.50%, which is significantly worse than the Sensex's drop of 1.47% during the same period.<BR><BR>While the company has demonstrated strong financial metrics, such as a 64.70% growth in net sales over the last six months and a substantial increase in profit before tax, the stock's price has been negatively impacted by a year-over-year profit decline of 28.9%. Additionally, although the stock has generated a return of 19.13% over the past year, the recent performance and the current price drop suggest that investors may be reacting to the falling profits despite the company's overall strong ability to service debt and attractive valuation compared to peers.<BR><BR>Overall, the combination of recent underperformance relative to the sector, declining profits, and the stock's movement below certain moving averages contributes to the current downward trend in Zydus Wellness Ltd's stock price.

Which are the latest news on Zydus Wellness?

Who are in the management team of Zydus Wellness?

The management team of Zydus Wellness includes Tarun Arora (CEO), Sharvil P Patel (Chairman), and several non-executive and independent directors, bringing diverse expertise to the company. Key members also include Ganesh N Nayak, Kulin S Lalbhai, Dharmishta N Rawal, Srivishnu Raju Nandyala, Akhil A. Monappa, Ashish Bhargava, and Nandish P. Joshi (Company Secretary).

The management team of Zydus Wellness includes the following key members:<BR><BR>1. **Tarun Arora** - Whole Time Director & CEO<BR>2. **Sharvil P Patel** - Chairman (Non-Executive)<BR>3. **Ganesh N Nayak** - Non-Executive & Non-Independent Director<BR>4. **Kulin S Lalbhai** - Non-Executive & Independent Director<BR>5. **Dharmishta N Rawal** - Non-Executive & Independent Director<BR>6. **Srivishnu Raju Nandyala** - Non-Executive & Independent Director<BR>7. **Akhil A. Monappa** - Independent Director<BR>8. **Ashish Bhargava** - Nominee<BR>9. **Nandish P. Joshi** - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Zydus Wellness do?

Zydus Wellness Ltd is a small-cap FMCG company specializing in health and wellness products, with net sales of ₹1,437 Cr and a net profit of ₹119 Cr as of June 2026. The company, originally founded in 1994, has a market cap of ₹16,934 Cr and operates under various key financial metrics.

Overview: <BR>Zydus Wellness Ltd operates in the FMCG industry and is categorized as a small-cap company.<BR><BR>History: <BR>Zydus Wellness Limited was incorporated on November 1, 1994, originally as 'Carnation Health Foods Limited'. The company underwent several name changes, ultimately becoming Zydus Wellness Limited on January 5, 2009. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,437 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 119 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 16,934 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 74.00 <BR>Industry P/E: 44 <BR>Dividend Yield: 0.23% <BR>Debt-Equity: 0.53 <BR>Return on Equity: 4.09% <BR>Price to Book: 2.87<BR><BR>Contact Details: <BR>Address: Zydus Corporate Park S No 536, Sarkhej-Gandhinagar Highway Ahmedabad Gujarat : 382481 <BR>Tel: 91-79-67775888 <BR>Email: investor.grievance@zyduswellness.in <BR>Website: http://www.zyduswellness.in

Who are the peers of the Zydus Wellness?

Zydus Wellness's peers include Cupid, Godfrey Phillips, P&G Hygiene, Hatsun Agro, Gillette India, Emami, Bikaji Foods, Honasa Consumer, and CCL Products. Zydus Wellness has average management risk and below average growth, with a 1-year return of 31.52%.

Peers: The peers of Zydus Wellness are Cupid, Godfrey Phillips, P&G Hygiene, Hatsun Agro, Gillette India, Emami, Bikaji Foods, Honasa Consumer, and CCL Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Godfrey Phillips, P&G Hygiene, and Gillette India, while Average management risk is found at Zydus Wellness, Cupid, and Honasa Consumer. Good management risk is noted at Hatsun Agro and Bikaji Foods, and the rest are rated as Excellent. Growth is Excellent for Godfrey Phillips and Bikaji Foods, while Good growth is seen at Cupid and Honasa Consumer. Below Average growth is noted for Zydus Wellness, P&G Hygiene, Hatsun Agro, Gillette India, Emami, and the rest.<BR><BR>Return Snapshot: Cupid has the highest 1-year return at 713.83%, while Godfrey Phillips has the lowest at -42.59%. Zydus Wellness's 1-year return of 31.52% is significantly higher than Godfrey Phillips but lower than Cupid. Additionally, Emami and Gillette India have negative six-month returns.

How big is Zydus Wellness?

As of 31st August, Zydus Wellness Ltd has a market capitalization of 16,934.00 Cr, with net sales of 4,537.10 Cr and a net profit of 188.20 Cr reported in the latest four quarters.

As of 31st August, Zydus Wellness Ltd has a market capitalization of 16,934.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Zydus Wellness reported net sales of 4,537.10 Cr and a net profit of 188.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with shareholder's funds amounting to 5,826.00 Cr and total assets of 10,189.90 Cr.

Should I buy, sell or hold Zydus Wellness Ltd?

Are Zydus Wellness Ltd latest results good or bad?

Zydus Wellness Ltd's latest results show strong revenue growth of 66.92% year-on-year, but a decline in net profit by 26.60% and margin compression raise concerns about profitability and operational efficiency. Investors should approach with caution, leaning towards a "HOLD" recommendation due to high valuation and profitability challenges.

Zydus Wellness Ltd's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales rising by 66.92% year-on-year to ₹1,437 crores. This indicates strong market demand and effective distribution expansion. However, the profitability metrics tell a different story. <BR><BR>Net profit for the quarter fell to ₹118.90 crores, down 26.60% from the previous quarter and 7.04% year-on-year. Additionally, both operating and PAT margins contracted, with operating margins decreasing to 16.90% and PAT margins to 8.32%. This margin compression raises concerns about the company's operational efficiency and cost management, especially given the backdrop of rising interest costs and a significant increase in debt.<BR><BR>Overall, while the revenue growth is commendable, the decline in profitability and margins suggests challenges that could impact the sustainability of this growth. Investors may need to exercise caution, as the company's elevated valuation at 76 times trailing earnings, significantly above the industry average, may not be justified given these profitability concerns. The current assessment leans towards a "HOLD" recommendation, indicating that while the company shows potential, it requires close monitoring for improvements in profitability and margin stability.

When is the next results date for Zydus Wellness Ltd?

The next results date for Zydus Wellness Ltd is 18 May 2026.

The next results date for Zydus Wellness Ltd is scheduled for 18 May 2026.

Is Zydus Wellness overvalued or undervalued?

As of November 6, 2025, Zydus Wellness is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 49.20 and a recent 1-week decline of 8.76%, despite a strong year-to-date return of 14.50%.

As of 6 November 2025, the valuation grade for Zydus Wellness has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios include a PE ratio of 49.20, an EV to EBITDA of 44.54, and a Price to Book Value of 0.25, which suggest that the stock is trading at a premium compared to its earnings and asset value.<BR><BR>In comparison to its peers, Zydus Wellness has a lower PE ratio than Hindustan Unilever, which stands at 54.11, and Nestle India, which has a PE of 81.85. However, the overall valuation of Zydus Wellness remains expensive in the context of the FMCG sector, where many peers are also categorized as very expensive. Despite a strong year-to-date return of 14.50% compared to the Sensex's 6.62%, the stock's recent performance has been lackluster, with a 1-week decline of 8.76%, reinforcing the notion that it may be overvalued at current levels.

How has been the historical performance of Zydus Wellness?

Zydus Wellness has shown consistent growth in net sales and profits from March 2020 to March 2025, with net sales increasing from 1,766.82 Cr to 2,708.90 Cr and operating profit peaking at 393.30 Cr, despite some fluctuations in profit margins and cash flow. Total liabilities rose to 6,297.20 Cr, while cash flow from operations improved to 380.00 Cr.

Answer:<BR>The historical performance of Zydus Wellness shows a consistent growth trajectory in net sales and profit over the years, with notable fluctuations in profit margins and cash flow.<BR><BR>Breakdown:<BR>Zydus Wellness has demonstrated significant growth in net sales, increasing from 1,766.82 Cr in March 2020 to 2,708.90 Cr in March 2025. The total operating income has mirrored this growth, reaching 2,708.90 Cr in March 2025, up from 1,766.82 Cr in March 2020. The operating profit (PBDIT) has also shown an upward trend, with a peak of 393.30 Cr in March 2025, although it experienced some fluctuations in previous years. Profit before tax reached 358.80 Cr in March 2025, while profit after tax stood at 346.90 Cr, indicating a healthy profitability despite a slight decline from the previous year. The company’s total liabilities increased to 6,297.20 Cr in March 2025, up from 5,468.89 Cr in March 2020, reflecting a rise in both short-term and long-term borrowings. Cash flow from operating activities improved significantly to 380.00 Cr in March 2025, compared to 259.00 Cr in March 2020, although the net cash outflow was recorded at -13.00 Cr in March 2025. Overall, Zydus Wellness has shown resilience and growth in its financial performance over the years.

Is Zydus Wellness technically bullish or bearish?

As of November 3, 2025, the trend is mildly bullish with daily moving averages supporting this view, but mixed signals from the MACD and KST suggest a cautious approach.

As of 3 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, suggesting mixed signals across time frames. Bollinger Bands are bullish on both weekly and monthly charts, reinforcing the positive outlook. However, the KST shows a bullish weekly trend but is mildly bearish monthly, indicating some caution. Overall, while there are bullish indicators, the mixed signals suggest a cautious approach.

Who are the top shareholders of the Zydus Wellness?

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited with 57.59%, Threpsi Care LLP at 7.27%, and individual investors at 5.91%. Mutual funds hold 11.61%, while foreign institutional investors account for 3.29%, with no pledged promoter holdings reported.

The top shareholders of Zydus Wellness include Zydus Lifesciences Limited, which holds the largest stake at 57.59%. Other significant shareholders are Threpsi Care LLP, with a holding of 7.27%, and individual investors, who collectively own 5.91%. Additionally, mutual funds are represented through 13 schemes, accounting for 11.61% of the shares, while foreign institutional investors (FIIs) hold 3.29% through 101 different entities. There are no pledged promoter holdings reported.

Has Zydus Wellness declared dividend?

Zydus Wellness Ltd has declared a 50% dividend, amounting to ₹5 per share, with an ex-date of July 19, 2024. The dividend yield is 0.26%, and total returns over the past five years stand at 51.68%.

Zydus Wellness Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 5<BR>- Ex-date: 19 Jul 24<BR><BR>Dividend Yield: 0.26%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.86%, the dividend return was 0%, resulting in a total return of -4.86%.<BR><BR>Over the past year, the price return was 3.51%, the dividend return was 0.26%, leading to a total return of 3.77%.<BR><BR>In the 2-year period, the price return was 28.84%, the dividend return was 0.67%, culminating in a total return of 29.51%.<BR><BR>For the 3-year period, the price return was 23.44%, the dividend return was 0.97%, resulting in a total return of 24.41%.<BR><BR>In the last 4 years, the price return was -7.19%, the dividend return was 0.96%, leading to a total return of -6.23%.<BR><BR>Over the past 5 years, the price return was 50.14%, the dividend return was 1.54%, resulting in a total return of 51.68%.<BR><BR>Overall, Zydus Wellness has declared a dividend, which contributes to a modest dividend yield. The total returns over various periods show a mix of positive and negative performance, with the 5-year period reflecting the strongest total return.